Looking Back and Managing Ahead

Terence R. Flotte, M.D. *Celia and Isaac Haidak Professor* Dean, Provost and Executive Deputy Chancellor

&

John Lindstedt

Executive Vice Chancellor for Administration and Finance

October 18, 2018



Progress Since Last Strategic Plan

Terence R. Flotte, M.D. *Celia and Isaac Haidak Professor* Dean, Provost and Executive Deputy Chancellor University of Massachusetts Medical School



Strategic Goals

As a leading academic health sciences center, these are our goals: to be the best academic health care system in New England; to be a model educational community of interprofessional, collaborative learners; to build a biomedical research and health care delivery workforce; to support a basic science research enterprise; to support the health care system as a laboratory and a community partner to improve health.

Education

As an innovative, interprofessional community of students and educators, we will build a health care delivery and biomedical research workforce that makes a lasting impact on human and community health.

Basic Research Continuing to be a leader in Massachusetts life sciences research, we will enhance the basic science enterprise and drive intellectual excitement, potential new therapies and long-term sustainability through the engine of discovery, with special focus on areas of existing worldclass strength.


Translational Research We will create a transformative research ecosystem that enables rapid development of products for clinical use, collaborates with the clinical system as a laboratory for clinical and translational research, and partners with the community to drive improvements in individual and population health.

lealth Care Delivery We will become the best academic health system in America based on measures of patient safety, quality, cost, patient satisfaction, innovation, education and caregiver engagement.

Education - Major Milestones Achieved To-Date

Background Information

		EDUCATION
	Objectives	
As an innovative, interprofessional community of students	Inter-professional Education	 Established the Liaison Committee for Interprofessional Curriculum (LCIC) to serve as the vehicle from which to implement interprofessional educational goals across the four schools (SOM, GSN, GSBS, GME) Established the pioneering Opioid Safe-prescribing Training Immersion (OSTI) Program to ensure all graduating medical and nurse practitioner students, as well as medical residents, are trained to be safe prescribers.
and educators, we will build a health care delivery and biomedical research workforce that makes a lasting impact on human and community health.	• New Teaching Affiliations	 New clinical teaching affiliations with Cape Cod Health and Baystate Health and opened the first regional campus of UMMS at Baystate Health. Designed and formally launched the new Population-based Urban and Rural Community Health or PURCH Track, which is offered at the UMMS- Baystate Campus; Welcomed the inaugural cohort of 22 PURCH students in the fall of 2017; appointed a new regional executive dean of UMMS- Baystate; successfully revised the UMMS Governance Document to formally establish 10 UMMS-Baystate clinical departments; Launched a process to provide UMMS-Baystate faculty appointments to more than 700 clinical educators at UMMS-Baystate.
	Class size expansion	• Increased class size from 125 to 162 (30% increase).






Basic Science - Major Milestones Achieved To-Date

Background Information

	Improve financial resou	rces dramatically and invest the resulting funds creatively
	A. Financial Resources	
In 2013, a Basic Science Work Group (convened in support	Increase Development	• Annual Fund Raising has increased from approximately \$32M per year and in FY18 exceeded \$54M. \$10M endowment for Institute Rare Disease Research, \$2M for GTC, approximately 3 new endowed chairs each year, three from donors from the Middle East who had no prior UMMS contact.
of Vision 2020) identified a number of proposals/goals	Clinical System Research Investment	 UMMHC invested \$700M over ten years upgrading EPIC, and at the same time agreed to cover half the costs of two critical research informatics interfaces: the Data Lake (a clinical data repository with all EPIC data in it) and Oncore (the Clinical Trials Management system). These two investments were key to our successful CTSA renewal.
which are summarized on this and the next several	Industry and other collaboration	 Created Office of EVC-IBD. Industry-funded research more than doubled from \$9.3M (FY13) to \$20.6M (FY18) We have begun reporting PPGs in the Annual Awards reports (from the Office of Sponsored Programs). The awards grew to \$7.9M for AY18, including grants in the Gene Therapy Center, BMP, BIB, MaPS, PMM and RTI.
pages along with major milestones achieved to-date.	• Promote entrepreneurship	 The office of the EVC-IBD has been created and major Newcos with series A funding in hand (at least \$30M each) have been spun off with major Venture Partners: 2rd Rock did 2 (Voyager and Fulcrum), Morningside (Chan) has done 2 (Bacainn and Apic Bio), Atlas has done 1 (Generation Bio), Bridge Bio has done 1 (Newco on Canavan), Glory Harvest Group (Li) has done 4 (cancer gene therapy, tethered miRNA, adipose-derived stem cells, DNA vaccine for HIV). With Atalanta (siRNA) about to be launched. MILESTONE FDA clinical approvals of UMMS technology-based products: patisiran (TTR-amyloidosis from Alnylam), spinraza (SMA from Ionis/Biogen), rabishield (Rabies MSb from SII/MBL), zinplava (C.Diff from Merck). Total \$100M captured in FY18.
	 Start new companies in our biotech park, in part by establishing Worcester based angel funding 	• The Glory Harvest Group companies will be in Biotech 3 of UMMS purchased Biotech Park.
	Maintain the sacrosanct status of the RTF system	• Done
	 Enlarge "bridge" fund to at least \$10M, and jettison its loan format 	• Will be launched in the 2 nd half of FY19 (\$1M)

UMMF New Commitments* - 5 Year View (\$millions)



*Commitment = New Pledges + New Cash Gifts + Outright Bequests + Gifts-in-Kind

Basic Science - Major Milestones Achieved To-Date

Background Information

Improve financial resources dramatically and invest the resulting funds creatively

B. Infrastructure Investment

Remodel the core system	 Reinstated RAC, put core subcommittees under the RAC. Add \$500k per year extra to Cores for investment.
• Utilize the Biotech Park buildings for incubator space, novel training opportunities, and a centralized core cluster ("innovation center")	 Started M2D2-Worcester serving both Biotech and Device development on the 6th floor basic wing. First three tenants are Biotech Companies.
Investment in high performance computing infrastructure	 Hired Jomol Mathew and have continued to expand resources internally, with the UMass system GHPCC and with Amazon and other contract resources.
• Expand and renew existing basic science departments to ensure vitality: replace faculty lost to retirement, lack of tenure, or transfer (inside or outside the institution)	• Have maintained pace of 6 to 7 Faculty hires per year.
Consider the pros and cons of departmental consolidations	Completed CDB, BNRI and Division of Preventive and Behavioral Medicine Merger.



Basic Science - Major Milestones Achieved To-Date

Background Information

Other							
Build a Bona Fide Cancer Center							
Working with the Clinical System, revamp basic and clinical efforts to create a cancer center	 Joint hire of Jonathan Gerber as adult Hematology-Oncology Division Chief, with Endowed Chair, three tenure lines and support for biorepository of bone marrow and AML samples. Joint hire of Jason Shohet, Pediatric Hematology-Oncology Division Chief, with Endowed Chair. 						
Utilize the revamped cancer center to build infrastructure for key basic science areas, including bioinformatics and human genetics	• With Jomol Mathew's help have brought the entire tumor repository of UMMHC Pathology into the cancer tissue bank.						
Address Other Areas of Cross-Disciplinary Strategic Interest							
 Ensure that other areas of cross-disciplinary strategic interest are addressed, including stem cell biology, drug resistance, and the microbiome Leveraged major investments from UMMS, MLSC, and HHMI to create cryoEM and use a focus for Structure-based Drug Resistance efforts. 							
Revise Graduate Student and Postdoctoral Fellow succeeding at diverse opportunities when they le	v Training to make it more flexible and to make our students much more capable of eave UMMS						
Enhance coursework, and student and faculty recruitment, in bioinformatics and chemistry	Revolutionized curriculum with Foundations core course.						
 Provide opportunities for training in non-academic careers (GSBS-, NIH- and Burroughs Welcome Fund- sponsored initiative in place through summer 2018) 	Found mechanisms to continue efforts of Cynthia Fuhrmann in GSBS.						
Provide enhanced training and mentorship for postdoctoral fellows	Continued support to Tony Imbalzano as Associate Dean for Post-doctoral studies.						
 Encourage broad opportunities for interdisciplinary interactions by students, postdocs, and faculty, including those from other UMass campuses 	Plan finalized to launch PhD/MBA with UMass Lowell, recruiting Fall 2018, enrolling Summer 2019.						
 Promote research-oriented interactions between the basic and clinical systems 	Continued robust investment and strategic alignment with CCTS and Office of Innovation and Business Development to ensure clinical translation.						

Translational Research and IT - Major Milestones Achieved To-Date


Background Information

We will create a transformative research ecosystem that enables rapid development of products for clinical use, collaborates with the clinical system as a laboratory for clinical and translational research, and partners with the community to drive improvements in individual and population health.

We will establish an information technology environment that enables the best care and patient experience, educates the finest caregivers and scientists and accelerates future therapies.

Translational Research	
• CTSA Renewal	 In August 2015, UMMS received a 4-year, \$17.3 million CTSA grant renewal. In 2016, MassBiologics was selected by the National Center for the Advancement of Translational Sciences (NCATS) to become a preferred, prequalified provider for contract process development and manufacturing of monoclonal antibodies and viral vectors. Investigators in the Department of Quantitative Health Sciences have received a new \$5,042,311 NCATS U01 grant as an adjunct to the CTSA, "Strengthening Translational Research in Diverse Enrollment (STRIDE)".
• Therapeutic Development	 MILESTONE FDA clinical approvals of UMMS technology-based products: patisiran (TTR-amyloidosis from Alnylam), spinraza (SMA from Ionis/Biogen), rabishield (Rabies MSb from SII/MBL), zinplava (C.Diff from Merck). Two therapeutics discovered at MassBiologics received FDA approval in FY2017: Merck's Zinplava to treat recucrrent c. difficile infection; and Serum Institute of India's Rabishield, a first-in-the-world monoclonal antibody for post-exposure prophylaxis of Rabies.
Restructuring Cancer Research	See Basic Science Section
Information Technology	
• IT Leadership Engagement	 Medical School CIO part of 24 person task force chosen by UMMHC CEO to select a new Electronic Medical Record System. IT Councils for both UMMS and UMass Memorial Medical Center coordinate strategic activities across both entities, including support for a long term electronic health record initiative. Developed 'date' lake strategy for clinical research database with UMass Memorial in anticipation of new electronic health record.
 Integration of Data 	 EPIC Data Lake ONCORE

Research Funding: Fiscal Years 2008 - 2018




Blue Ridge Institute for Medical Research (BRIMR) 2017 Ranking Tables of NIH Funding to US Medical Schools

UMMS Department (BRIMR Dept)	Total costs	Rank
MCCB & PMM (Anatomy/Cell Biology)	\$ 38,596,513	1
Emergency Medicine (Emergency Medicine)	\$ 2,144,589	5
BMP (Biochemistry)	\$ 12,435,629	14
GTC & RTI (Genetics)	\$ 13,465,983	14
Orthopedics (Orthopedics)	\$ 728,938	23
QHS (Public Health)	\$ 2,418,998	26
Neurobiology (Neurosciences)	\$ 5,469,864	27
Pathology (Pathology)	\$ 6,753,752	30
Neurology (Neurology)	\$ 6,580,903	32
Radiology (Radiology)	\$ 2,682,240	35
Medicine (Internal Medicine)	\$ 33,507,271	36
Family Medicine (Family Medicine)	\$ 25,511	41
Psychiatry (Psychiatry)	\$ 4,737,827	43
MAPS (Microbiology)	\$ 6,214,376	43
Pediatrics (Pediatrics)	\$ 3,197,740	49
Surgery (Surgery)	\$ 418,750	65
Ophthalmology (Ophthalmology)	No UMMS data No	UMMS data
Anesthesiology (Anesthesiology)	No UMMS data No	UMMS data
Dermatology (Dermatology)	No UMMS data No	UMMS data
Neurosurgery	No UMMS data No	UMMS data
OBGYN (OBGYN)	No UMMS data No	UMMS data
Otolaryngology (Otolaryngology)	No UMMS data No	UMMS data
Urology (Urology)	No UMMS data No	UMMS data
	\$ 139,378,884	
UMMS Ranked 32 out of 139	\$ 153,024,069	

Tenure/Tenure Track Faculty Trends

Year	Beginning # TTR/TEN	New Hires	Transfers to TTR	Transfers to NTT/Term	Ending # TTR/TEN	
AY2008	211	10	7	9	219	
AY2009	219	18	2	6	233	
AY2010	233	18	0	6	245	
AY2011	245	9	3	11	246	
AY2012	246	8	9	15	248	
AY2013	248	13	2	16	247	
AY2014	247	7	1	7	248	
AY2015	248	8	0	12	244	
AY2016	244	5	4	22	231	
AY2017	231	8	1	13	227	
AY2018	227	5	1	22	211	
AY2019 YTD	211	1	0	1		



Tenure/Tenure Track Faculty Commitments

Unfilled Committed Slots April 2017	New Committed Slots September 2018	Revised Unfilled Slots September 2018	Filled T/ Slots September 2018	Total T/TT Slots Filled/ Committed
40	11.5	51.5	211	262.5



Planned Faculty Recruitment

FY	Examples of Departments Recruiting
FY19 (8)	BIB, Medicine-Hemonc, Medicine-Hepatology, MCCB, QHS, Pathology, GTC, RTI
FY20 (8)	Neurobiology, Medicine-Hepatology, Medicine-HemOnc, Medicine-ID, PSB, MaPS, GTC, RTI
FY21 (7)	Dermatology, Pediatrics, HemOnc, Diabetes, MCCB, QHS, Pathology, PSB
	University of Massachusetts Medical School



Research Density of School Buildings for F&A Purposes

(FY17 Space Survey Data)

Building	Building Name	Research SF	Usable SF*	Research Density	Max Potential Research Density**	% of Efficiency	Vacant lab space	Vacant Office Space	Vacant space
001	MEDICAL SCHOOL	63,365	394,861	16.05%	41.00%	39.14%	25,833	11,756	37,590
005	SHAW	2,907	21,099	13.78%	30.00%	45.93%	116	5,170	5,286
010	LAZARE RESEARCH(LRB)	148,354	222,355	66.72%	75.00%	88.96%	16,044	2,751	18,794
013	AMB CARE CENTER(ACC-7th)	1,378	13,484	10.22%	75.00%	13.63%	-	-	-
014	BIOTECH ONE(1st flr)	2,279	8,165	27.91%	75.00%	37.21%	201	1,975	2,176
015	BIOTECH TWO	44,367	60,256	73.63%	75.00%	98.17%	2,931	56	2,987
108	ALBERT SHERMAN CENTER(ASC)	119,121	270,949	43.96%	51.00%	86.20%	10,184	5,920	16,104
Grand Total		381,771	991,169				55,309	27,628	82,937

*Usable SF excludes vacant, common, circulation and O&M areas

**Based on intended use of all space regardless of current occupancy and assuming 25% for other activities aside from research (education, clinical, public service)



Looking Back and Managing Ahead

John Lindstedt, Executive Vice Chancellor for Administration and Finance



UMMS Financial Results (FY 2013-2018)

(\$ in thousands)	FY		FY2013 FY2014		FY2015		FY2016		FY2017		FY2018	
Operating revenues												
State appropriations	\$	41,136	\$	44,620	\$	45,843	\$	50,634	\$	52,250	\$	54,559
Independent Business Lines (non-grant activity)		367,576		355,527		323,577		337,259		379,715		305,391
Grants and Contracts		192,863		189,355		193,704		192,354		201,638		196,444
Clinical System		50,357		53,276		52,623		58,040		56,746		54,416
Net Tuition and fees		14,367		16,245		16,867		18,612		21,455		25,289
Other revenues		252,559		257,126		146,668		320,368		260,999		334,404
Total operating revenues		918,858		916,149		779,282		977,267		972,803		970,503
Operating expenses												
Academic Operations		377,298		423,857		305,883		492,265		396,941		486,741
Independent Business Lines (non-grant activity)		354,473		337,473		305,560		307,280		343,596		266,806
Grants		188,738		188,049		200,453		188,321		201,594		196,023
Total operating expenses		920,509		949,379		811,896		987,866		942,131		949,570
Operating Margin												
		(1,651)		(33,230)		(32,614)		(10,599)		30,672		20,933
		-0.2%		-3.6%		-4.2%		-1.1%		3.2%		2.2%
Non-operating Revenue and Expenses												
Net Non-operating revenue and expenses		34,551		28,772		19,536		(5,943)		27,645		(8,700)
Total Increase in Net Position	\$	32,900	\$	(4,458)	\$	(13,078)	\$	(16,542)	\$	58,317	\$	12,233



Comparative Statement of Net Position

(\$ in thousands)	2013		2018		Chang	ge
Assets						
Cash & Investments						
Quasi-endowment	\$ 102,794	\$	110,476	\$	7,682	7.5%
Other Cash and Investments	135,284		278,266		142,982	105.7%
Cash Held by Trustee	30,389		127		(30,262)	-99.6%
Receivables	134,589		134,248		(341)	-0.3%
Inventories	13,015		13,365		350	2.7%
Orgs	27,628		44,253		16,625	60.2%
Property, Plant & Equipment	1,079,000		954,168		(124,832)	-11.6%
Other Assets	 3,995		5,482		1,487	37.2%
Total Assets	 1,526,694		1,540,385		13,691	0.9%
Liabilities						
Accounts & Wages Payable	77,993		64,920		(13,073)	-16.8%
Debt	720,309		625,673		(94,636)	-13.1%
Due to Related Organizations	4,744		4,564		(180)	-3.8%
Other Liabilities	 51,434		136,894		85,460	166.2%
Total Liabilities	854,480		832,051		(22,429)	-2.6%
Net Assets						
Invested in Plant	385,239		330,954		(54,285)	-14.1%
Restricted	43,745		74,459		30,714	70.2%
Unrestricted	 243,230		302,921		59,691	24.5%
Total Net Assets	672,214		708,334		36,120	5.4%
Total Liabilities & Net Assets	\$ 1,526,694	<u>\$</u>	1,540,385	<u>\$</u>	13,691	0.9%
Endowment Balance	\$ 68,643	\$	108,314		39,671	57.8%
(on UMass Foundation Books)						



Comparative Statement of Net Position, continued (FY2013-2018)

Total Assets have increased from \$1.527 B to \$1.540B (a \$13.7M or 1% increase).

• The increase in cash and investments is offset by a decrease in property, plant and equipment due to increased depreciation expense related to capital improvements.

Total Liabilities have decreased from \$854M to \$832M (a \$22M or 3% decrease).

• Driven primarily by a decrease in debt from \$720M to \$625M (a \$95M or 13% decrease).

Total Net Assets have grown from \$672M to \$708M (a \$36M or 5% increase).

Endowments have grown from \$69M to \$108M (a \$40M or 58% increase).



UMMS 5-Year Financial Plan (FY 2019-2023)

(\$ in thousands)	FY2018 Actual		FY2019		FY2020		FY2021		FY2022		FY2023	
Operating revenues												
State appropriations	\$	54,559	\$	52,744	\$	53,882	\$	55,027	\$	56,203	\$	57,380
Independent Business Lines (non-grant activity)		305,391		367,504		384,387		402,086		420,638		449,077
Grants and Contracts		196,444		211,561		219,791		229,830		240,211		252,593
Clinical System		54,416		57,646		59,936		62,508		60,744		62,262
Net Tuition and fees		25,289		27,474		30,044		31,748		32,660		33,645
Other revenues		334,404		231,393		236,591		240,272		244,971		237,892
Total operating revenues		970,503		948,322		984,631		1,021,471		1,055,427		1,092,849
Operating expenses												
Academic Operations		486,741		399,664		405,213		409,778		413,864		420,492
Independent Business Lines (non-grant activity)		266,806		332,380		347,606		363,565		380,289		397,846
Grants		196,023		211,561		219,791		229,830		240,211		252,593
Total operating expenses		949,570		943,605		972,610		1,003,173		1,034,364		1,070,931
Operating Margin												
As presented to BoT Nov 2017		20,933		4,717		12,021		18,298		21,063		21,918
		2.2%		0.5%		1.2%		1.8%		2.0%		2.0%
Current Target				17,903		19,693		20,429		21,109		21,857
				2.0%		2.0%		2.0%		2.0%		2.0%
Gap				13,186		7,672		2,131		46		(61)
Non-operating Revenue and Expenses												
Net Non-operating revenue and expenses		(8,700)		4,067		4,968		5,229		6,427		6,817
Total Increase in Net Position		12,233		8,784		16,989		23,527		27,490		28,735



5-Year Financial Plan: Assumptions (FY2019-2023)

State Appropriation

- FY'18 = Flat
- FY'19 '22 = Growth based on CBA

Grants & Contracts

- FY'18 = 7.5% over FY'17 budget (based on current research awards data), flat with FY'17 actual
- FY'19 '22 = 4%
- Reduced Federal funding would have offsetting impact on revenue and expense

SOM Class Size

- FY'18 = class size of 162
- FY'19 = Completion of 3-year plan to increase tuition
- FY'21 = All classes at 162
- Aggregate new revenue impact of \$14 M annually

Financial Aid

• Grows with total tuition charges

Annual gift revenue

- \$6 to \$7 M per year
- Does not include endowment receipts
- Total Achievement remains consistent with annual goals agreed to with the President's Office

5-Year Financial Plan: Assumptions (Continued FY2019-2023)

UMMHC Participation Payment:

- FY'18 '20 No Payment
- FY'21 = \$2.1 M
- FY'22 = \$3.2 M

Salary increases at 2% per year.

Fringe benefits and pension rates remain flat.

Faculty Recruitment:

- Maintain current spending level of \$10-11 M per year
- Recruitments remain at 6-8 per year

Campus Capital Expenditures:

- New project capital commitments of approximately \$20 M annually
- Deferred maintenance spending; a local investment of \$20 M per year from FY'18 '20
- NO STATE CAPITAL FUNDING ASSUMED

Key Financial Success Factors (FY2019-2023)

Main Campus:

Commonwealth Medicine:


MassBiologics:

• Increased class size, including acceptance of out-of-state students

- UMMS and Baystate Health have partnered to establish the Medical School's first-ever regional campus, UMMS-Baystate, in Springfield
- Basic and translational research growth
- Investment in licensing activities; potential for IP / licensing revenue to grow by an additional \$20 - \$30 million annually
- Continued philanthropic efforts
- Support & grow Center for Health Care Financing
- Expand business lines to other states
- Continually evaluate low margin businesses
- Leadership succession
- Grow margin by a minimum of 3% annually
- Maintain or increase Td sales
- Continue to develop and grow contract manufacturing
 - Add a further processing line
- Manage royalty stream
 - Current IP portfolio
 - Develop new licenses



FY2018 Mission-Based Funding Model



University of Massachusetts UMASS. Medical School Umassmed.edu